Better, safer therapy for the treatment of cancer
Targeted, systemic, tumor-specific treatment right at your fingertips
The TheraBionic P1 device and patented radio frequencies treat the cancer cells that are specific to the cancer type. For example, liver cancer frequencies are solely effective in the treatment of liver cancer. The same frequencies would not be effective in treating a breast cancer tumor, and vice versa. Tumor-specific refers to the patented, specific frequencies which TheraBionic Inc. has identified as effective in treating specific forms of cancer.
Safe, convenient, effective
The TheraBionic P1’s tumor-specific frequencies are administered via a metal spoon, which is placed on the tongue and delivers radio frequencies throughout the body. The level of radio frequencies delivered is lower than the level of radio frequencies delivered by a cellphone. The metal spoon is connected to the P1 device, which is slightly larger than a cellphone, making it portable and convenient for the recommended treatment of 60 minutes, three times daily.
In multiple studies conducted over more than two decades, patients undergoing treatment using the TheraBionic P1 device, did not experience the debilitating side effects associated with other cancer-fighting therapies including loss of appetite, diarrhea, and irritation of the palms and soles. In patients with liver cancer*, survival rates increased by 34 percent using the TheraBionic P1 therapy.
* Currently, the TheraBionic P1 device is FDA-approved for the treatment of hepatocellular carcinoma (HCC) in patients 18 and older who have failed first and second line therapies.
Meet Our Team
Boris Pasche, MD PhD
Boris Pasche is the co-inventor of the TheraBionic technology. He is the co-founder of TheraBionic Inc. and TheraBionic GmbH. Together with Alexandre Barbault he hypothesized and demonstrated that tumor-specific frequencies block the growth of tumors. Pasche is also the president and CEO of Karmanos Cancer Institute, an NCI-designated Comprehensive Cancer Center in Detroit, MI.
CEO, Board Chair, Co-Founder
Alexandre Barbault
Alexandre Barbault is the co-inventor of the TheraBionic technology. He is co-founder of TheraBionic Inc. and TheraBionic GmbH. Together with Boris Pasche he has developed novel methods and devices for the identification of tumor-specific frequencies in patients with a diagnosis of cancer.
Co-Inventor
Valerie Pasche, MD
Valerie Pasche is a trained anesthesiologist with extensive experience with medical devices as well as compliance with European and FDA guidelines. Since 2021, she oversees TheraBionic Inc. operations, marketing, and clinical grant applications. Dr. V. Pasche work with TheraBionic Inc. has been funded by the National Cancer Institute.
Chief Operating Officer
Stefan Grant, MD JD MBA
Stefan Grant is TheraBionic Inc. General Counsel. He oversees TheraBionic’s business development, strategic alliances, and patent portfolio. Dr. Grant is also Director of the Tulane Cancer Center and Deputy Director of the Louisiana Cancer Research Center.
General Counsel
Questions?
Read the FAQ or contact us at info@therabionic.com